Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
June 28, 2013 at 16:40 PM EDT
Insmed Incorporated (NASDAQ: INSM ), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced that the Company will report top-line results from its European and Canadian Phase 3 study of
